EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myelomaAccess, Myeloma3 July 2026
European Commission approves subcutaneous isatuximab for the treatment of multiple myelomaAccess9 June 2026
New ways to administer daratumumab and isatuximab get positive recommendations from EMAAccess10 April 2026
Join our webinar “The generics market in Europe and implications for cancer treatment and care”Access, MPE5 March 2026
AELCLÉS presents report highlighting the high socioeconomic impact of oncohaematological diseases in SpainMPE19 February 2026
MPE response to EMA consultation on their “Reflection paper on patient experience data (PED)”Myeloma3 February 2026
US Food and Drug Administration (FDA) issues draft guidance on minimal residual diseaseAccess28 January 2026
